Alector Licensing Deal with Genentech, Inc. Worth $100M
Alector entered into an exclusive global licensing agreement with Genentech to develop and commercialize AL050, a brain-penetrant engineered GCase enzyme replacement therapy for Parkinson’s disease. Alector will receive a $100 million upfront payment and is eligible for up to $1.17 billion in additional milestone payments plus tiered royalties on net sales. The deal extends Alector's cash runway into 2029 while allowing the company to retain ownership of its proprietary Alector Brain Carrier platform.
- Value
- $100M
- Counterparty
- Genentech, Inc.